CAB Boucher

1.2k total citations · 1 hit paper
5 papers, 695 citations indexed

About

CAB Boucher is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, CAB Boucher has authored 5 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 5 papers in Virology and 1 paper in Molecular Biology. Recurrent topics in CAB Boucher's work include HIV Research and Treatment (5 papers), HIV/AIDS drug development and treatment (5 papers) and HIV/AIDS Research and Interventions (4 papers). CAB Boucher is often cited by papers focused on HIV Research and Treatment (5 papers), HIV/AIDS drug development and treatment (5 papers) and HIV/AIDS Research and Interventions (4 papers). CAB Boucher collaborates with scholars based in Netherlands, France and United States. CAB Boucher's co-authors include Philippe Halfon, Philippe Clevenbergh, P. Dellamonica, N Montagne, J. Durant, Pere Simonet, Pascal Del-Giudice, P. Del Giudice, V. Mondain and Sigrid C. J. M. Vervoort and has published in prestigious journals such as The Lancet, Antiviral Therapy and HIV Medicine.

In The Last Decade

CAB Boucher

5 papers receiving 667 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

1999 559 citations J. Durant, Philippe Clevenbergh et al. The Lancet profile →

Peers

Countries citing papers authored by CAB Boucher

Since Specialization

Citations

This map shows the geographic impact of CAB Boucher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by CAB Boucher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites CAB Boucher more than expected).

Fields of papers citing papers by CAB Boucher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by CAB Boucher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by CAB Boucher. The network helps show where CAB Boucher may publish in the future.

Co-authorship network of co-authors of CAB Boucher

This figure shows the co-authorship network connecting the top 25 collaborators of CAB Boucher. A scholar is included among the top collaborators of CAB Boucher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with CAB Boucher. CAB Boucher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy 2018 ·HIV Medicine ·(unknown), (unknown), Casper Rokx, D.M. Burger, Annelies Verbon, Jeroen J. A. van Kampen, CAB Boucher, Bart Rijnders, Linos Vandekerckhove	12
2	Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV‐1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations 2012 ·HIV Medicine ·Marieke Pingen, (unknown), (unknown), (unknown), Birgitte B. Simen, Martin Schutten, CAB Boucher	10
3	Increased risk of early virological failure in non‐European HIV‐1‐infected patients in a Dutch cohort on highly active antiretroviral therapy 2005 ·HIV Medicine ·(unknown), Eelko Hak, Sigrid C. J. M. Vervoort, (unknown), CAB Boucher, Rob Schuurman, (unknown)	24
4	Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up 2000 ·Antiviral Therapy ·Philippe Clevenbergh, J. Durant, Philippe Halfon, P. Del Giudice, V. Mondain, N Montagne, (unknown), CAB Boucher, P. Dellamonica	90
5	Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial breakdown → 1999 ·The Lancet ·J. Durant, Philippe Clevenbergh, Philippe Halfon, Pascal Del-Giudice, (unknown), Pere Simonet, N Montagne, CAB Boucher, (unknown), P. Dellamonica	559

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact